The Pharma Data

MARCH 13, 2022

That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore

Immune Response 52

Immune Response Protein Medicine Genetics 52

XTalks

NOVEMBER 6, 2020

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. million from Canada’s National Research Council (NRC) to support the clinical advancement of bacTRL-Spike.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

The Pharma Data

MARCH 8, 2022

SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. Researchers led by Prof. In this way, the viral RNA escapes early recognition by the central antiviral immune-receptor RIG-I.

Immune Response 52

Immune Response RNA Protein Genetics 52

XTalks

JUNE 15, 2022

The Novavax candidate NVX-CoV2373 is a protein-based vaccine developed using recombinant nanoparticle technology. protein that triggers the immune system to generate antibodies against the virus. Adjuvants can help boost the effectiveness of a vaccine and elicit a stronger immune response. Novavax Vaccine Research.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

FEBRUARY 19, 2024

In a recent study published by Weill Cornell Medicine in the Journal of Infectious Diseases , researchers have reported the potential of Moderna’s experimental mRNA vaccine in protecting adults against CMV, which could potentially also stop the transmission of the virus from mothers to their infants during pregnancy.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Cloudbyz

MARCH 6, 2024

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics.

Gene 72

Gene Immune Response Manufacturing Gene Therapy 72

Cloudbyz

MARCH 5, 2024

Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.

Development 77

Development Drugs Manufacturing Immune Response 77

pharmaphorum

NOVEMBER 28, 2021

Omicron has more mutations affecting the spike protein targeted by vaccines than any other strain identified to date – up to 32 mutations versus eight for the Delta variant – but its not clear how that will affect the transmissibility and virulence of the virus. 1.1.529 version of its recombinant protein-based shot.

Vaccination 105

Vaccination Vaccine Protein Genetics 105

pharmaphorum

JULY 14, 2021

At the same time, the UK’s National Institute for Health and Care excellence (NICE) is developing guidance to help doctors manage the cases of vaccine-induced immune thrombocytopenia and thrombosis (VITT) and low blood platelet counts that have been seen with the COVID-19 vaccines.

Vaccination 116

Vaccination Vaccine Immune Response Protein 116

XTalks

MAY 1, 2023

This makes Qalsody the first approved treatment to target a genetic cause of ALS. While the exact causes of ALS are not fully understood, research suggests that the mutation of SOD1 may be linked to the development of the condition. To date, over 200 mutations in the SOD1 gene have been associated with the development of ALS.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. Half of the recovered COVID-19 patients studied had T cell responses to highly networked epitopes identified by the research team. 1.351 Beta, P1 Gamma, and B.1.617.2

Vaccination 52

Vaccination Vaccine Research Immune Response 52

Drug Discovery World

JULY 25, 2023

Background Lymphocyte-activation gene 3, or LAG-3, is a gene that provides the genetic information to make a cell surface molecule with biologic effects on T-cell function. Two years after this discovery, his team was able to show that the LAG-3 protein was a ligand for MHC Class II molecules like CD4.

Immune Response 98

Immune Response Gene Protein Antibody 98

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. The research was published online recently in Proceedings of the National Academy of Sciences.

Immune Response 52

Immune Response Genetic Engineering Engineer Research 52

XTalks

NOVEMBER 30, 2023

Over the last 35 years, substantial strides have been made in tackling HIV/AIDS, propelled by advancements in medical research, enhanced accessibility to treatment and prevention and a more comprehensive understanding of the virus. World AIDS Day offers an occasion for reflection on the strides achieved thus far.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

NOVEMBER 30, 2020

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. Vaccines Taskforce and National Institute for Health Research played pivotal roles in the rapid recruitment and enrollment of volunteers.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

The Pharma Data

APRIL 22, 2023

While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation. Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

The Pharma Data

NOVEMBER 9, 2020

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. President of Research and Development, Novavax. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Drug Discovery World

APRIL 14, 2023

The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. June’s award lecture will be held on Sunday April 16 at 4:30pm ET.

Genetics 52

Genetics Research Medicine Clinical Research 52

pharmaphorum

MARCH 10, 2021

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 The latest research is published in the New England Journal of Medicine. 1 mutations, as well as variants from the UK and South Africa.

Vaccination 60

Vaccination Vaccine Genetic Engineering Engineer 60

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. Shape’s RNA editing technology could potentially modify the amount of a key regulatory protein in the body or treat genetic diseases. and Leila Zegna, director of the Kabuki Syndrome Foundation.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

XTalks

NOVEMBER 23, 2020

Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

Delveinsight

SEPTEMBER 23, 2021

Boehringer stated that the Abexxa’s generation aims at cancer-specific proteins situated throughout the mobile versus proteins at the mobile membrane broadening the selection of possible cancer antigen objectives. 858’s drug candidates include proteins, which regulate RNA and immune response.

RNA 61

RNA Gene Therapy Gene Protein 61

pharmaphorum

JANUARY 17, 2023

Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution.

Vaccination 89

Vaccination Vaccine In-Vivo In-Vitro 89

The Pharma Data

DECEMBER 22, 2020

So far, the new variant only seems to spread more easily, with no evidence of higher virulence (ability to cause harm), researchers at Northwestern Medicine in Chicago explained. Ison explained that “variants occur when there is a change in the genetic material of the virus that results in a change in proteins the virus makes.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JULY 6, 2021

New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Hemophilia is a rare, genetic bleeding disorder in which a person’s blood does not clot properly. ePoster Abstract # OC48.2 Abstract # OC72.2

Protein 52

Protein RNA Marketing Development 52

The Pharma Data

OCTOBER 27, 2020

AavantiBio’s strategic partnership with University of Florida’s Powell Gene Therapy Center provide their foundational research in rare genetic disorders. The company’s lead program is aimed at Friedrich’s Ataxia, a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. Be Biopharma .

Gene 52

Gene Gene Therapy Medicine Genetics 52

STAT News

MARCH 6, 2023

It works with commercial partners and researchers at the Washington University School of Medicine in St. Neoantigen vaccines are designed to target certain proteins called neoantigens on tumor cells. and established in 2020, acknowledged that the $83,000 charge might raise eyebrows.

Vaccination 98

Vaccination Vaccine Drugs Clinical Trials 98

Delveinsight

DECEMBER 22, 2020

It substantially increased the production of the blood-clotting protein factor IX, which is the factor missing for hemophilia B patients, in all the enrolled patients. Ultragenyx (RARE) and Mereo collaborated to develop and commercialize setrusumab , a monoclonal antibody for a rare genetic disorder osteogenesis imperfecta (OI).

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

The Pharma Data

DECEMBER 31, 2020

Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. People with severe COVID-19 have low proportions of antibodies that target the spike protein. There are also other branches of the immune system involved.

Antibody 52

Antibody Research Bacteria Genetics 52

Drug Discovery World

MAY 30, 2023

As the US National Cancer Research Month draws to a close, we asked experts from across the industry “What do you feel has been the most exciting development in cancer research in the last five years?” Here are their answers.

Research 52

Research Drugs Protein RNA 52

XTalks

SEPTEMBER 17, 2020

While clinical researchers occasionally need to identify and validate a new surrogate endpoint for a given trial, choosing endpoints that have been previously used as the basis of NDAs and BLAs can clear the path to eventual approval. Dietary changes, including restriction of salt and animal protein, are also recommended.

Trials 98

Trials Gene Hormones Clinical Trials 98

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron. Regeneron has shared these results with the U.S.

Antibody 40

Antibody Trials Production Clinical Trials 40

Drug Discovery World

JULY 22, 2022

As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. Going beyond the limits of immune checkpoint inhibitors (ICIs). Though results have been mixed, there is no doubt that HIS mice are an effective tool to study ICIs 3.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

The Pharma Data

DECEMBER 18, 2020

The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. The vaccine contains a small piece of the SARS-CoV-2 virus’s mRNA that instructs cells in the body to make the virus’s distinctive “spike” protein. Director of the FDA’s Center for Biologics Evaluation and Research.

Vaccination 52

Vaccination Vaccine Production Manufacturing 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., The development and manufacturing of the antibody cocktail has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S.

Antibody 52

Antibody Trials Production Clinical Trials 52

XTalks

JUNE 5, 2023

Abrysvo is an unadjuvanted vaccine and is composed of two preF proteins selected to optimize protection against RSV A and B strains. “A Research indicates that RSV can interfere with the functioning of dendritic cells, vital for initiating an antiviral response. How Does Abrysvo Work?

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

World of DTC Marketing

DECEMBER 29, 2020

These vaccines were developed using different “platform technologies” that involve slotting genetic material from the virus into a tried and tested delivery package. While such platform technologies are a non-traditional approach, that does not mean they are untested. The power of social media also came into play.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307